To assess whether ustekinumab is more effective than azathioprine to prevent endoscopic Endoscopic Postoperative Recurrence in patients with Crohn´S Disease
Latest Information Update: 07 Dec 2020
At a glance
- Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 07 Dec 2020 New trial record
- 13 Oct 2020 Primary endpoint (endoscopic POR evaluated 6 months (M6) after intestinal resection or following stoma closure, defined as Rutgeerts index i2.) has been met as per results presented at the 28th United European Gastroenterology Week
- 13 Oct 2020 Results presented at the 28th United European Gastroenterology Week